J
Jeffrey S. Wasser
Researcher at University of Connecticut
Publications - 50
Citations - 4258
Jeffrey S. Wasser is an academic researcher from University of Connecticut. The author has contributed to research in topics: Romiplostim & Pembrolizumab. The author has an hindex of 20, co-authored 49 publications receiving 3913 citations. Previous affiliations of Jeffrey S. Wasser include Memorial Sloan Kettering Cancer Center & University of Connecticut Health Center.
Papers
More filters
Journal ArticleDOI
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
James N. George,Steven H. Woolf,Gary E. Raskob,Jeffrey S. Wasser,Louis M. Aledort,P. J. Ballem,Victor S. Blanchette,James B. Bussel,Douglas B. Cines,John G. Kelton,Alan E. Lichtin,Robert McMillan,JA Okerbloom,David H. Regan,Indira Warrier +14 more
TL;DR: This report begins with a brief summary of the panel’s recommendations, followed by a more detailed analysis of its methodology, the findings of the comprehensive literature review, and a full presentation of the recommendations.
Journal ArticleDOI
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
TL;DR: Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenECTomised patients with ITP and treatment safety was good.
Journal ArticleDOI
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
James B. Bussel,David J. Kuter,James N. George,Robert McMillan,Louis M. Aledort,George T. Conklin,Alan E. Lichtin,Roger M. Lyons,Jorge Nieva,Jeffrey S. Wasser,Israel Wiznitzer,Reggie Kelly,Chien Feng Chen,Janet L. Nichol +13 more
TL;DR: AMG 531 caused no major adverse events and increased platelet counts in patients with ITP, and increases in the platelet count were dose-dependent.
Journal ArticleDOI
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell,Omid Hamid,David Smith,Todd M. Bauer,Jeffrey S. Wasser,Anthony J. Olszanski,Jason J. Luke,Ani Sarkis Balmanoukian,Emmett V. Schmidt,Yufan Zhao,Xiaohua Gong,Janet Maleski,Lance Leopold,Thomas F. Gajewski +13 more
TL;DR: Epacadostat in combination with pembrolizumab generally was well tolerated and had encouraging antitumor activity in multiple advanced solid tumors and was comparable to historical controls for monotherapies.
Journal ArticleDOI
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
David J. Kuter,James B. Bussel,Adrian C. Newland,Ross I. Baker,Roger M. Lyons,Jeffrey S. Wasser,Jean-François Viallard,Gail Macik,Mathias J. Rummel,Kun Nie,Susie Jun +10 more
TL;DR: It is demonstrated that romiplostim was safe and well‐tolerated over 614 patient‐years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment.